The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2025 | The current role of brentuximab vedotin in Hodgkin lymphoma
Amanda Cashen, MD, Washington University School of Medicine, St. Louis, MO, comments on the evolving role of brentuximab vedotin (BV) in Hodgkin lymphoma (HL), noting that the use of the nivolumab-AVD regimen may push BV back into later lines of therapy. Dr Cashen suggests that, as more patients will now be naive to BV in the relapsed setting, there is potential to revisit its use in consolidation after autologous stem cell transplant (autoSCT). This interview took place at the SOHO Italy Annual Conference 2025 in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So brentuximab with AVD has been demonstrated in the ECHELON-1 study to be superior to ABVD with six-year progression-free and overall survival benefit; however the BV-AVD regimen is currently being supplanted by a nivo-AVD which I think is going to push brentuximab back into the later lines of therapy, it’s an appealing drug to incorporate in the salvage setting, and it also makes me revisit the role of consolidative brentuximab vedotin after autologous stem cell transplant...
So brentuximab with AVD has been demonstrated in the ECHELON-1 study to be superior to ABVD with six-year progression-free and overall survival benefit; however the BV-AVD regimen is currently being supplanted by a nivo-AVD which I think is going to push brentuximab back into the later lines of therapy, it’s an appealing drug to incorporate in the salvage setting, and it also makes me revisit the role of consolidative brentuximab vedotin after autologous stem cell transplant. The AETHERA trial many years ago now demonstrated that consolidation with 16 cycles of brentuximab after autologous transplant led to improvements in progression-free survival over placebo control arm, but the use of brentuximab consolidation had kind of fallen out of favor as we were using that drug more often in frontline and second-line therapy. Now that we’re going to be seeing more patients who are naive to brentuximab in the relapsed setting, I can see revisiting the use of consolidative brentuximab for more patients especially if they are naive to the drug or responded well to it in a salvage regimen.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
